Skip to content
Yog Pharma
CardiovascularNon-selective beta blocker with alpha-1 blocking activity

Carvedilol is a non-selective beta blocker with alpha-1 blocking activity indicated for heart failure, left ventricular dysfunction after myocardial infarction and hypertension. We supply it to US manufacturers of tablets and extended-release capsules.

CAS72956-09-3406.5 g/molC24H26N2O4
2D structure of Carvedilol.

Data from PubChem (CID 2585) and FDA’s substance registry

CAS number

72956-09-3

Molecular formula

C24H26N2O4

Molecular weight

406.5g/mol

FDA UNII

IUPAC name

1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol

InChIKey

OGHNVEJMJSYVRP-UHFFFAOYSA-N

Appearance
White to off-white powder.
Solubility
Practically insoluble in water and gastric fluid. Freely soluble in dimethyl sulfoxide, soluble in methylene chloride and methanol, and sparingly soluble in ethanol.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

With so little solubility in water, particle size distribution is usually part of the specification. Carvedilol phosphate, used in extended-release capsules, is a separate API.

On the US market

Reference product
CoregNDA 020297
Approved ANDAs
10 with a marketed product
Approved forms and strengths
  • Tablet 3.125 mg, 6.25 mg, 12.5 mg, 25 mg

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com